BR0315188A - Composto de cefem - Google Patents

Composto de cefem

Info

Publication number
BR0315188A
BR0315188A BR0315188-3A BR0315188A BR0315188A BR 0315188 A BR0315188 A BR 0315188A BR 0315188 A BR0315188 A BR 0315188A BR 0315188 A BR0315188 A BR 0315188A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
formula
amino
hydrogen
Prior art date
Application number
BR0315188-3A
Other languages
English (en)
Other versions
BRPI0315188B1 (pt
BRPI0315188B8 (pt
Inventor
Hidenori Ohki
Shinya Okuda
Toshio Yamanaka
Masaru Ohgaki
Ayako Toda
Kohji Kawabata
Satoshi Inoue
Keiji Misumi
Kenji Itoh
Kenji Satoh
Original Assignee
Astellas Pharma Inc
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc, Wakunaga Pharma Co Ltd filed Critical Astellas Pharma Inc
Publication of BR0315188A publication Critical patent/BR0315188A/pt
Publication of BRPI0315188B1 publication Critical patent/BRPI0315188B1/pt
Publication of BRPI0315188B8 publication Critical patent/BRPI0315188B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTOS DE CEFEM". A invenção presente refere-se a um composto da fórmula [I]: onde R^ 1^ é alquila inferior, hidroxi-alquila (inferior) ou halo-alquila (inferior), e R^ 2^ é hidrogênio ou grupo protetor amino, ou R^ 1^ e R^ 2^ estão ligados entre si e formam alquileno inferior ou alquenileno inferior; R^ 3^ é hidrogênio ou alquila inferior; R^ 4^ é R^ 5^ é carboxi ou carboxi protegido; e R^ 6^ é amino ou amino protegido, ou um sal farmaceuticamente aceitável do mesmo, um processo para preparar um composto da fórmula [I], e uma composição farmacêutica compreendendo um composto da fórmula [I] em mistura com um condutor farmaceuticamente aceitável.
BRPI0315188A 2002-10-30 2003-10-27 composto e composição farmacêutica BRPI0315188B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (en) 2002-10-30 2003-10-27 Cephem compounds

Publications (3)

Publication Number Publication Date
BR0315188A true BR0315188A (pt) 2005-09-06
BRPI0315188B1 BRPI0315188B1 (pt) 2017-04-25
BRPI0315188B8 BRPI0315188B8 (pt) 2021-05-25

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315188A BRPI0315188B8 (pt) 2002-10-30 2003-10-27 composto e composição farmacêutica

Country Status (20)

Country Link
US (2) US7129232B2 (pt)
EP (1) EP1556389B9 (pt)
JP (1) JP4448821B2 (pt)
KR (1) KR101023035B1 (pt)
AR (1) AR041729A1 (pt)
AT (1) ATE368042T1 (pt)
BE (1) BE2016C002I2 (pt)
BR (1) BRPI0315188B8 (pt)
CA (1) CA2504730C (pt)
DE (1) DE60315178T3 (pt)
DK (1) DK1556389T6 (pt)
ES (1) ES2290498T7 (pt)
FR (1) FR16C0004I2 (pt)
HK (1) HK1086566A1 (pt)
HU (1) HUS1600008I1 (pt)
LU (1) LU92943I2 (pt)
NL (1) NL300793I1 (pt)
PT (1) PT1556389E (pt)
TW (1) TWI319403B (pt)
WO (1) WO2004039814A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529887A (en) * 2001-05-01 2005-05-27 Fujisawa Pharmaceutical Co Cephem compounds
JP4448821B2 (ja) * 2002-10-30 2010-04-14 アステラス製薬株式会社 セフェム化合物
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE602004026451D1 (de) * 2003-09-18 2010-05-20 Astellas Pharma Inc Cephem-verbindungen
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2007119511A1 (en) * 2006-03-16 2007-10-25 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
ITFE20060029A1 (it) * 2006-10-17 2008-04-18 Gruppo Kemon Spa Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
US8883772B2 (en) 2007-10-09 2014-11-11 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
RU2606131C2 (ru) * 2011-05-13 2017-01-10 Эррэй Биофарма Инк. СОЕДИНЕНИЯ ПИРРОЛИДИНИЛМОЧЕВИНЫ И ПИРРОЛИДИНИЛТИОМОЧЕВИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ TrkA
JP6151257B2 (ja) 2011-09-09 2017-06-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 肺内感染症の治療方法
EP2628730B1 (en) * 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
JP6186001B2 (ja) 2012-09-27 2017-08-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． タゾバクタムアルギニン抗菌性組成物
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US20140274999A1 (en) * 2013-03-14 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3100732A1 (en) * 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
HUE045340T2 (hu) 2014-05-15 2019-12-30 Array Biopharma Inc 1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor
CN106795175A (zh) 2014-08-15 2017-05-31 默沙东公司 头孢菌素化合物的合成
US10221196B2 (en) 2014-08-15 2019-03-05 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
WO2016028670A1 (en) * 2014-08-18 2016-02-25 Merck Sharp & Dohme Corp. Salt forms of ceftolozane
WO2016095860A1 (en) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
WO2016100897A1 (en) * 2014-12-18 2016-06-23 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
US10214543B2 (en) 2014-12-30 2019-02-26 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
ES2729026T3 (es) 2015-06-29 2019-10-29 Sandoz Ag Procedimiento para la preparación de derivados de carbamoilamino pirazol
WO2017042188A1 (en) 2015-09-08 2017-03-16 Sandoz Ag Process for preparing ceftolozane from 7-aminocephalosporanic acid (7-aca)
WO2017096472A1 (en) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
CN109195967A (zh) 2016-06-06 2019-01-11 默沙东公司 头孢洛扎的固体形式和制备方法
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (en) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Combination therapies for multi-drug resistant pathogens
CN109369535A (zh) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (pt) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) * 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
NZ529887A (en) * 2001-05-01 2005-05-27 Fujisawa Pharmaceutical Co Cephem compounds
JP4448821B2 (ja) * 2002-10-30 2010-04-14 アステラス製薬株式会社 セフェム化合物
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE602004026451D1 (de) * 2003-09-18 2010-05-20 Astellas Pharma Inc Cephem-verbindungen

Also Published As

Publication number Publication date
HK1086566A1 (en) 2006-09-22
HUS1600008I1 (hu) 2016-03-29
DE60315178T2 (de) 2008-04-30
WO2004039814A1 (en) 2004-05-13
FR16C0004I1 (fr) 2016-03-25
NL300793I2 (pt) 2016-03-15
NL300793I1 (pt) 2016-03-15
JP4448821B2 (ja) 2010-04-14
US20070037786A1 (en) 2007-02-15
DK1556389T3 (da) 2007-11-26
AR041729A1 (es) 2005-05-26
ATE368042T1 (de) 2007-08-15
US7129232B2 (en) 2006-10-31
EP1556389B1 (en) 2007-07-25
BRPI0315188B1 (pt) 2017-04-25
DE60315178D1 (de) 2007-09-06
EP1556389B3 (en) 2015-04-01
LU92943I2 (fr) 2016-03-14
TW200410977A (en) 2004-07-01
KR20050084897A (ko) 2005-08-29
PT1556389E (pt) 2007-11-08
FR16C0004I2 (fr) 2017-01-06
BRPI0315188B8 (pt) 2021-05-25
ES2290498T7 (es) 2015-07-10
BE2016C002I2 (pt) 2023-03-07
JP2006506459A (ja) 2006-02-23
DK1556389T6 (da) 2015-05-11
CA2504730A1 (en) 2004-05-13
EP1556389B9 (en) 2015-09-09
TWI319403B (en) 2010-01-11
CA2504730C (en) 2011-04-12
DE60315178T3 (de) 2015-06-18
US20040132994A1 (en) 2004-07-08
KR101023035B1 (ko) 2011-03-24
EP1556389A1 (en) 2005-07-27
ES2290498T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
BR0315188A (pt) Composto de cefem
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR0316375A (pt) Diazinopirimidinas
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BRPI0212346B1 (pt) Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica.
BRPI0308495B8 (pt) composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto
BG104998A (en) Isothiazole derivatives useful as anticancer agents
CA2383409A1 (en) Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2304713A1 (en) Biphenyl-5-alkanoic acid derivatives and use thereof
BR0013248A (pt) Inibidores da adesão celular
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
AP2001002358A0 (en) Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4- pyrrolidin-1-yl-butyl)ureido]-isothiazole-4-carboxilic acid amide and method of production.
HUP0302362A2 (hu) Fejfájás, migrén, émelygés és hányás kezelésére alkalmas gyógyászati készítmény
BR9810911A (pt) Composto, e, processo para tratar câncer em um mamìfero
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
MXPA02004555A (es) Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF